PharmacoMRI of Parkinson Disease
Based on studies showing better responsiveness of motor versus cognitive symptoms to Parkinson's Disease medication, also known as dopaminergic treatments, the investigators hypothesize that comparison of resting state networks in the on versus off medication state in Parkinson's Disease patients will show greater effects on brain networks associated with motor control.
|Study Design:||Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||A Pilot Study of the Drug Effects on Brain Connectivity of Parkinson's Disease|
- Efficacy of Parkinson's Medication on Brain Connectivity [ Time Frame: 2 and 1/2 hours ] [ Designated as safety issue: No ]Two 25-30 minute MRI scans will be conducted. The first when the patient is OFF PD medications for approximately 12 hours and the second following dosage of PD medication thereby being ON PD medication for the 25-30minute scan. There is an hour between the two scans that the patient will complete a series of cognitive assessments: UPDRS, MOCA, medical history, geriatric depression scale, and family history.
- Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex. [ Time Frame: 1 hour ] [ Designated as safety issue: No ]Correlation coefficient between UPDRS III score and independent components analysis network strength in left parietal cortex. UPDRS III is the Unified Parkinson's Disease Rating Scale composite motor score.
|Study Start Date:||June 2011|
|Study Completion Date:||July 2012|
|Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
Experimental: On / Off medication
Subjects undergo MRI scanning in the medication off state and 1 hour after receiving medications.
Equivalent amount of carbidopa-levodopa will be provide to you
Subject participation includes two 25-30 minute MRI scans. The subject will arrive in the "off" state (PD medications withheld for approximately 12 hours prior to the scan). Following the initial scan, the subject will receive 125% of his or her usual daily morning dose of PD medications which is calculated as levodopa dose equivalents (LDE) and is given as carbidopa-levodopa. The subject will then wait for an hour allowing for the medication to begin working. During this time the subject will complete cognitive assessments, questionnaires regarding the history and current state of PD, and motor assessments. The subject will then undergo a second MRI scan of approximately 25-30 minutes. The subject after completing the second MRI scan is free to leave. The entire study is approximately 2 and 1/2 hours long.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01528592
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Principal Investigator:||Darren R Gitelman, MD||Northwestern University|